Clinical Trial Update: Study to Evaluate SID 530 Compared to Taxotere [Phase 3]

View source ↗

Summary

Phase 3 study evaluating SID 530 versus Taxotere in non-small cell lung cancer has completed. The trial evaluated efficacy and safety outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SID 530
• Taxotere (docetaxel)

Snippet

Sponsor: SK Chemicals Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED